Bio-Rad Laboratories, Inc. (BIO) Q4 2022 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET

Company Participants

Edward Chung - Vice President, Investor Relations

Ilan Daskal - Chief Financial Officer

Andrew Last - Chief Operating Officer

Norman Schwartz - President and Chief Executive Officer

Simon May - President, Life Science Group

Conference Call Participants

Patrick Donnelly - Citigroup Inc.

Dan Leonard - Credit Suisse

Brandon Couillard - Jefferies Group LLC

Jack Meehan - Nephron Research LLC

Operator

Good afternoon, ladies and gentlemen. Thank you for attending today’s Bio-Rad Fourth Quarter and Full Year 2022 Earnings Results Conference Call. My name is Tia [ph], and I will be your moderator for today’s call. [Operator Instructions]

I would now like to pass the conference over to your host, Edward Chung with Bio-Rad. Please proceed.

Edward Chung

Thanks, Tia. Good afternoon, everyone, and thank you for joining us today. Today, we will review the fourth quarter and full year 2022 financial results and provide an update on key business trends for Bio-Rad.

With me on the call today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Simon May, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group.

Before we begin our review, I would like to caution everyone that we will be making forward-looking statements about management’s goals, plans and expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these forward-looking statements are commentary, regarding the impact of the COVID-19 pandemic on Bio-Rad’s results and operations and steps Bio-Rad is taking in response to the pandemic.

Our actual results may differ materially from these plans and expectations, and it is difficult to predict the full extent of potential impact the pandemic could have in the future. You should not place undue reliance on these forward-looking statements, and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business.

The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks will include references to non-GAAP financials including net income and diluted earnings per share, which are financial measures that are not defined under Generally Accepted Accounting Principles. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release.